Phaseline

Companies › AFT Pharmaceuticals

AFT Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Other; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Combogesic® IV
Fixed-dose combination of acetaminophen and ibuprofen
PTGS1, PTGS2Phase 3Acute PainMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07225634Combogesic® IVPhase 3Acute PainOtherMar 2027

From the company's SEC filings

Complete response letters from FDA

Targets

PTGS1 (1) PTGS2 (1)

Companies with the same targets

ZetrOZ Caribou Biosciences Sana Biotechnology Brainfarma Industria Química e Farmacêutica S/A Laboratorios Silanes S.A. de C.V. Sirnaomics

Companies built like this

Laboratorios Silanes S.A. de C.V. Huons Biopharma Neuren Pharmaceuticals Tetra Discovery Partners Prove pharm

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.